Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Improvements in the Treatment of High-Risk Thyroid Cancer

예후가 좋지 않은 갑상선암에 대한 최신 치료 방침

  • Lee, Eun Kyung (Division of Endocrinology, Center for Thyroid Cancer, National Cancer Center)
  • 이은경 (국립암센터 갑상선암센터 내분비내과)
  • Received : 2022.05.10
  • Accepted : 2022.05.18
  • Published : 2022.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Thyroid cancer is one of the slow-growing tumors with excellent oncological outcomes. However, a small set of patients with unexpectedly severe outcomes are usually ignored. Anaplastic thyroid cancer (ATC) remains one of the most aggressive and lethal solid tumors. Recently, dabrafenib and trametinib combination therapy or neoadjuvant BRAF induction therapy has shown promising results. In addition, a combination of targeted drugs, immunotherapy, surgery, and radiation therapy can improve overall survival in ATC patients. Another disease for which there is no breakthrough treatment is radioactive iodine-refractory differentiated thyroid cancer (DTC). To date, multikinase inhibitors (sorafenib, lenvatinib) targeting the growth factor signaling pathway have been developed and approved as anticancer agents for patients with advanced DTC. This review includes results from multikinase inhibitors to the emergence of new target molecules, including rearrangements during transformation (RET) and tropomyosin receptor kinase (TRK).

Keywords

Acknowledgement

This work was supported by the Creative Media Service in National Cancer Center, Korea.

References

  1. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767. https://doi.org/10.1056/NEJMp1409841
  2. Yi KH, Lee EK, Kang H-C, Koh Y, Kim SW, Kim IJ, et al. 2016 revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. IJT. 2016;9:59-126.
  3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA. 2021;71:7-33.
  4. Registry KCC. Annual report of cancer statistics in Korea in 2018. Ministry of Health and Welfare; 2020.
  5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71:209-249.
  6. Hong S, Won Y-J, Lee JJ, Jung K-W, Kong H-J, Im J-S, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301. https://doi.org/10.4143/crt.2021.291
  7. Gottlieb JA, Hill CS, Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290:193-197. https://doi.org/10.1056/NEJM197401242900404
  8. Network NCC. Thyroid Carcinoma; 2009.
  9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133. https://doi.org/10.1089/thy.2015.0020
  10. Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa Sylvia L, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
  11. National Comprehensive Cancer Network. Thyroid Carcinoma V.1.2021; 2021.
  12. Yoo S-K, Song YS, Park YJ, Seo J-S. Recent improvements in genomic and transcriptomic understanding of anaplastic and poorly differentiated thyroid cancers. ENM. 2020;35:44-54.
  13. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
  14. Song YS, Park YJ. Genomic characterization of differentiated thyroid carcinoma. ENM. 2019;34:1-10.
  15. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. The Lancet. 2014;384:319-328. https://doi.org/10.1016/S0140-6736(14)60421-9
  16. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. https://doi.org/10.1056/NEJMoa1406470
  17. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31-42. https://doi.org/10.1210/jc.2012-2909
  18. Lee EK, Kim SM, Kim BH, Kim MJ, Lim DJ, Kim MH, et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: A Korean multicenter retrospective study. Thyroid. 2019;29:1811-1819. https://doi.org/10.1089/thy.2019.0022
  19. Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: A Korean multicenter study. Thyroid. 2018;28:340-348. https://doi.org/10.1089/thy.2017.0356
  20. Yan Z, Yang M, Lai CL. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. Clin Endocrinol (Oxf). 2021;95:478-488. https://doi.org/10.1111/cen.14479
  21. Brose MS, Schlumbeger M, Jeffers M, Kappeler C, Meinhardt G, Pena CE. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase 3 DECISION trial. Clin Cancer Res. 2019;25:7370-7380. https://doi.org/10.1158/1078-0432.ccr-18-3439
  22. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: A clinician's perspective. Semin Oncol. 2014;41 Suppl 2:S1-S16.
  23. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Annals of Oncology. 2019;30:viii23-viii30. https://doi.org/10.1093/annonc/mdz282
  24. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739. https://doi.org/10.1056/NEJMoa1714448
  25. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747. https://doi.org/10.1038/s41571-018-0113-0
  26. Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. 2019;25:1422-1427. https://doi.org/10.1038/s41591-019-0542-z
  27. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835. https://doi.org/10.1056/NEJMoa2005651
  28. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491-501. https://doi.org/10.1016/S2213-8587(21)00120-0
  29. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7.
  30. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncology. 2020;6:1397-1404. https://doi.org/10.1001/jamaoncol.2020.3362
  31. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark Jr TJ, et al. 2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid. 2021;31:337-386. https://doi.org/10.1089/thy.2020.0944
  32. Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31:1076-1085. https://doi.org/10.1089/thy.2020.0322